🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. Nerve block with liposomal bupivacaine and intravenous analgesia

    The First People's Hospital of Lianyungang

    Liposomal Bupivacaine

    approved other active

    1 trial

  2. Nicorandil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stable Angina

    approved small molecule completed

    1 trial

  3. Nifedipine GITS

    The First People's Hospital of Lianyungang

    Hypertension

    approved small molecule active

    1 trial

  4. Nocardia rubra Cell Wall Skeleton

    The First People's Hospital of Lianyungang

    Diabetic Foot Ulcer

    approved small molecule active

    1 trial

  5. Norfloxacino Sandoz 400 mg comprimidos EFG

    The George Institute

    Hospitalized patients with decompensated cirrhosis, diagnosed with bacterial infection evolution lasting for 48 hours or less.

    approved small molecule active

    1 trial

  6. Normal saline

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    STEMI - ST Elevation Myocardial Infarction

    approved small molecule active

    1 trial

  7. Nucala 100 mg solution for injection in pre-filled pen, Nucala 100 mg solution for injection in pre-filled syringe, Nucala 100 mg solution for injection in pre-filled syringe, Nucala 100 mg solution for injection in pre-filled pen, Nucala 100 mg solution for injection in pre-filled pen, Nucala 100 mg solution for injection in pre-filled syringe

    GlaxoSmithKline

    severe asthma

    approved small molecule active

    1 trial

  8. ONTAK (denileukin difitox, DAB389IL-2)

    LIGAND PHARMACEUTICALS INC

    Lymphoma, T-Cell, Cutaneous

    approved small molecule completed

    1 trial

  9. OPDIVO 10 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets

    The George Institute

    Renal carcinoma

    approved small molecule active

    1 trial

  10. ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, RoActemra 162 mg solution for injection in pre-filled syringe., ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, RoActemra 162 mg solution for injection in pre-filled syringe., ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg sol

    The George Institute

    Adults patients suffering from rheumatoid arthritis and in adequate response to one or two targeted treatments.

    approved small molecule active

    1 trial

  11. Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications]

    approved small molecule active

    1 trial

  12. Ofatumumab

    Novartis Pharmaceuticals

    Relapsing Multiple Sclerosis

    approved mab completed

    1 trial

  13. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    AML (Acute Myeloid Leukemia)

    approved small molecule active

    1 trial

  14. Omvoh 100 mg solution for injection in pre-filled syringe, Omvoh 100 mg + 200 mg solution for injection in pre-filled syringe, Omvoh 100 mg solution for injection in pre-filled pen, Omvoh 100 mg solution for injection in pre-filled pen, Omvoh 100 mg + 200 mg solution for injection in pre-filled syringe, Omvoh 100 mg solution for injection in pre-filled syringe, Omvoh 100 mg solution for injection in pre-filled pen, Omvoh 100 mg + 200 mg solution for injection in pre-filled pen, Omvoh 100 mg + 200 mg solutio

    Eli Lilly Co.

    severely active ulcerative colitis (US) and CD (Crohn’s disease)

    approved small molecule active

    1 trial

  15. Optimal hypoglycemic treatment

    The First People's Hospital of Lianyungang

    Type2 Diabetes

    approved other active

    1 trial

  16. Oral Zonisamide Therapy

    Affiliated Hospital of Nantong University

    Epilepsies, Partial

    approved small molecule active

    1 trial

  17. Oral consumption

    BRIGHT MINDS BIOSCIENCES INC.

    Growth Acceleration

    approved other completed

    1 trial

  18. Ornithine aspartate granule

    The First People's Hospital of Lianyungang

    Non-alcoholic Fatty Liver Disease

    approved small molecule completed

    1 trial

  19. Oxycodone Hydrochloride

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Analgesia, Patient-Controlled

    approved small molecule active

    1 trial

  20. Ozempic 1 mg solution for injection in pre-filled pen, Dapagliflozin 10 mg film-coated tablets

    The George Institute

    Type 2 diabetes

    approved small molecule active

    1 trial

  21. Ozempic 1 mg solution for injection in pre-filled pen, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 2 mg solution for injection in pre-filled pen, Ozempic 0.25 mg solution for injection in pre-filled pen

    Disc Medicine

    Diabetic foot ulcer

    approved small molecule active

    1 trial

  22. PALEXIA Retard 50 mg tabletten met verlengde afgifte

    Disc Medicine

    chronic postoperative pain

    approved small molecule active

    1 trial

  23. PCIA group

    The First People's Hospital of Lianyungang

    Postoperative Pain

    approved other active

    1 trial

  24. PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources